Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - STANDARD DIVERSIFIED INC. | t67237_8k.htm |
Exhibit 99.1
 |
N E W S R E L E A S E |
| FOR IMMEDIATE RELEASE | 111 Pencader Drive | ||
| Newark, DE 19702 | |||
| P 302.456.6789 | |||
| F 302.861.3730 | |||
| T 800.544.8881 | |||
| www.sdix.com |
Thomas
Bologna and David Wurzer Join
SDIX
Board of Directors
NEWARK, DE (February 24, 2010) –
SDIX (Nasdaq: SDIX), a leading provider of biotechnology-based products
and services for a broad range of life science, biotechnology, diagnostic, and
food safety applications, today announced Thomas Bologna and David Wurzer have
been appointed to the Board of Directors, effective February 22, 2010. Messrs.
Bologna and Wurzer will be members of Class I and their terms are scheduled to
expire at the annual meeting of stockholders to be held in 2011.
Mr.
Bologna is currently President and Chief Executive Officer and a member of the
Corporate Board of Directors at Orchid Cellmark, Inc., a DNA testing company
with its headquarters in Princeton, New Jersey. He has a proven track
record of over twenty years leading venture-backed private and public
biotechnology companies, turnarounds, and highly profitable healthcare divisions
and subsidiaries of Fortune 500 companies. Mr. Bologna holds an MBA and Bachelor
of Science degree from New York University.
Mr.
Wurzer is currently Managing Director of Investments at Connecticut Innovations
(CI), the State’s “venture capital arm.” He is responsible for sourcing
and analyzing investment opportunities, leading CI investments in
entrepreneurial high-tech ventures and advising portfolio companies. He
has over 29 years of financial experience with growth-oriented companies,
including direct involvement with raising capital, strategic transactions and
mergers & acquisitions, for both start-up companies and publicly-held
entities. Mr. Wurzer holds a BBA degree in Accountancy from the University
of Notre Dame.
“We are
excited to have Tom and David join the SDIX board,” said Fran DiNuzzo, President
and CEO of SDIX. “Both gentlemen are successful executives who have business and
governance experience in the Life Science marketplace. They will add
additional knowledge to the SDIX board and to the leadership of the Company. We
look forward to their insight and contributions as we continue to transition
SDIX into a growth business.”
About
SDIX
SDIX is a
biotechnology company, expert at creating advantage by providing a broad range
of quality, innovative and effective immuno-solutions to the Pharmaceutical,
Biotechnology, Diagnostics, and Food Safety markets. For 20 years, SDIX has
developed antibodies which advance its customers’ immuno-based work – reducing
time, labor, and costs while increasing accuracy and reliability of
results.
SDIX
offers a full suite of integrated immuno-solution capabilities including assay
design, development, and production. In life science markets, SDIX
capabilities are being used to help discover the mechanisms of disease,
facilitate the development of new drugs, and provide mechanisms for rapid
diagnosis. For more information, visit www.sdix.com.
###
This
news release may contain forward-looking statements reflecting SDI's current
expectations. When used in this press release, words like “anticipate”, “could”,
“enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”,
“should”, “project”, “plan” and similar expressions as they relate to SDI are
intended to identify said forward-looking statements. Investors are cautioned
that all forward-looking statements involve risks and uncertainties, which may
cause actual results to differ from those anticipated by SDI at this time. Such
risks and uncertainties include, without limitation, changes in demand for
products, the application of our technologies to various uses, delays in product
development, delays in market acceptance of new products, retention of customers
and employees, adequate supply of raw materials, inability to obtain or delays
in obtaining fourth party, including AOAC, or required government approvals, the
ability to meet increased market demand, competition, protection of intellectual
property, non-infringement of intellectual property, seasonality, and other
factors more fully described in SDI's public filings with the U.S. Securities
and Exchange Commission.
SDIX
Company Contact:
Kevin
Bratton
Chief
Financial Officer
(302)
456-6789
kbratton@sdix.com